araag2/HINT huggingface dataset:
Clinical trial NCT01378533 (phase 3, status: unknown status)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: epirubicin, cyclophosphamide, paclitaxel, carboplatin, g-csf
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patient must accept the modified radical mastectomy

          2. Patients with histologically confirmed ER(-) PR(-) and HER-2(-)

          3. Positive axillary lymph nodes;negative axillary lymph node with age< 35 years or Ⅲ
             grade or intravascular cancer embolus.

          4. Age between 18 years to 65 years

          5. Able to give informed consent

          6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or
             1.

          7. Not pregnant, and on appropriate birth control if of child-bearing potential.

          8. Adequate bone marrow reserve with ANC > 1000 and platelets > 100,000.

          9. Adequate renal function with serum creatinine < 2.0.

         10. Adequate hepatic reserve with serum bilirubin < 2.0, AST/ALT < 2X the upper limit of
             normal, and alkaline phosphatase < 5X the upper limit of normal. Serum bilirubin > 2.0
             is acceptable in the setting of known Gilbert's syndrome.

         11. No active major medical or psychosocial problems that could be complicated by study
             participation.

        Exclusion Criteria:

          1. received neo-adjuvant therapy

          2. Cardiac dysfunction documented by an ejection fraction less than the lower limit of
             the facility normal by multi-gated acquisition (MUGA) scan, or 45% by echocardiogram.
             -The rate of Disease recurrence

          3. Uncontrolled medical problems.

          4. Evidence of active acute or chronic infection.

          5. Pregnant or breast feeding.

          6. Hepatic, renal, or bone marrow dysfunction as detailed above.
Clinical trial NCT01829243 (phase 3, status: completed)
Conditions: fibromyalgia, neurocognition
ICD codes: M79.7
Drugs: milnacipran, placebo
SMILES: CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 to 65 years.

          -  Specific diagnosis of FM by the participant's rheumatologist or physician, including
             written confirmation, from a physician, of the FM diagnosis.

          -  Confirmation of the FM diagnosis by American College of Rheumatology Criteria and a
             physical tender point examination.

          -  Ability to give informed consent.

          -  If female, nonpregnant/nonlactating.

          -  If a sexually active female of reproductive potential, must be using adequate
             contraception (i.e., oral contraceptives, barrier protection, or prior tubal ligation)
             during the trial.

        Exclusion Criteria:

          -  Bipolar disorders, any psychotic disorder.

          -  the existence of concomitant rheumatological disorders, including rheumatoid
             arthritis, systemic lupus erythematosus, Hashimoto's disease, Sjogren's syndrome or
             scleroderma.

          -  Substance dependence (except nicotine dependence) in the previous 3 months.

          -  Currently suicidal or high suicide risk.

          -  Serious or unstable medical disorders.

          -  Any psychotropic drug treatment in the previous 2 weeks before screening.

          -  A positive urine pregnancy test.

          -  Screening laboratory values three times the limits of normal or judged clinically
             significant by the investigator.

          -  History of hypersensitivity to milnacipran.

          -  Seizure disorder, traumatic brain injury, any CNS disorder that affects cognitive
             status.

          -  Concomitant meds: A minimum of 30 days on stable dose of analgesics and a minimum of 4
             week washout from antidepressants and fibromyalgia specific medication ( e.g.
             pregabalin, neurontin) and supplements ( St John's wort, SAM-E).

          -  Narrow angle glaucoma.
Clinical trial NCT00151424 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: asenapine, placebo, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Currently suffering from an acute exacerbation of schizophrenia.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable medical condition. Have any other psychiatric disorder
             other than schizophrenia as a primary diagnosis.
Clinical trial NCT01244815 (phase 3, status: completed)
Conditions: bipolar disorder, pediatric
ICD codes: R63.31, R63.32, G47.33, Z68.51, Z68.54, Z68.52, Z68.53
Drugs: asenapine, placebo to match asenapine, rescue medication
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Participants who (or whose parent/legal representative) are able to give written
             informed consent.

          -  Participants must be 10 years of age or older and 17 years of age or younger at the
             time of treatment assignment (randomization).

          -  Participants must have a diagnosis of bipolar I disorder, confirmed by structured
             interview at screening.

          -  Participants must not be pregnant or lactating, and those who are sexually active or
             become sexually active during the trial, and of child-bearing potential, must be using
             a medically accepted form of birth control.

          -  Participants will be required to have stopped taking certain psycho-active medications
             prior to baseline.

          -  Participants must have a caregiver, or other responsible person living with them who
             agrees to provide support to the participant to ensure study and procedure compliance.

        Exclusion criteria:

          -  Diagnosis of bipolar II disorder, or other form of bipolar or psychotic disorder.

          -  Known or suspected mental retardation.

          -  Substance abuse, or dependence, within the past 6 months.

          -  There is risk of self-harm or harm to others.

          -  There is a history of tardive dyskinesia or dystonia.

          -  Pregnancy or lactation during the study.

          -  History of seizure disorder.

          -  Participation in any other clinical trial at the same time.

          -  A family member who is part of the study staff or is directly involved with the study.

          -  Other medical conditions determined by the study staff to possibly interfere with the
             study safety and efficacy evaluations.
Clinical trial NCT00649025 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: flutiform 250/10, skp-fluticasone, flovent fluticasone hfa
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Main Inclusion Criteria:

          -  ≥ Age 12 years at the Screening Visit.

          -  History of asthma for 12 months prior to the Screening Visit.

          -  Documented use of an inhaled corticosteroid for at least 4 weeks prior to the
             Screening Visit.

          -  Steroid-requiring patient

          -  patients must demonstrate (1) an FEV1 of 40% to 80% (inclusive) of predicted normal
             values at both the Screening and Baseline Visits and (2) documented reversibility
             within 12 months of the Screening Visit, defined as a ≥ 15%

        Main Exclusion Criteria:

          -  Life-threatening asthma within the past year or during the Run-In Period.

          -  History of systemic (oral or injectable) corticosteroid medication within 3 months
             before the Screening Visit.

          -  An upper or lower respiratory infection within 4 weeks prior to the Screening Visit or
             during the Run-In Period.

          -  Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary
             disease [COPD], cystic fibrosis, bronchiectasis).

          -  A smoking history equivalent to "10 pack years" (i.e., at least 1 pack of 20
             cigarettes /day for 10 years or 10 packs/day for 1 year, etc.).

          -  Current smoking history within 12 months prior to the Screening Visit.

          -  Previous exposure to FlutiForm
Clinical trial NCT00300755 (phase 3, status: completed)
Conditions: gastroesophageal reflux
ICD codes: K21.9, K21.00, K21.01
Drugs: pantoprazole sodium enteric-coated spheroid
SMILES: COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Ability to undergo endoscopy with required biopsy

          -  Ages 1 through 5 years

          -  Endoscopically confirmed GERD by positive endoscopic evidence of reflux related
             esophagitis or positive histologic evidence of esophagitis consistent with GERD Other
             inclusions apply.

        Exclusion Criteria:

          -  History or presence of upper gastrointestinal anatomic or motor disorders

          -  Known current or active cow's milk allergy

          -  Malignancy

          -  Other exclusions apply.
Clinical trial NCT00598806 (phase 3, status: completed)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: apaziquone, placebo
SMILES: CN1C(\C=C\CO)=C(CO)C2=C1C(=O)C=C(N1CC1)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        All of the following questions must be answered "Yes" in order for the patient to
        participate in the study.

          1. Has the patient given written informed consent?

          2. Is the patient at least 18 years old?

          3. Does the patient have transitional cell carcinoma of the bladder with clinically
             apparent tumor Ta, grade G1-G2?

          4. If the patient is a female of childbearing potential, is she using an
             acceptable/effective method of contraception?

          5. If the patient is a female of childbearing potential, has she had a negative serum
             pregnancy test within the past 14 days?

          6. Is the patient willing and able to abide by the protocol?

        Exclusion Criteria:

        All of the following questions must be answered "No" in order for the patient to
        participate in the study.

          1. Does the patient have more than 5 bladder tumors?

          2. Does any single bladder tumor exceed 3.5 cm in diameter?

          3. Does the patient have a single, primary bladder tumor <0.5 cm and has no previous
             diagnosis of bladder cancer?

          4. Has the patient ever received EOquin(r)?

          5. Does the patient have, or has the patient ever had, any bladder tumor known to be
             other than tumor Ta or grade G1 or G2 (low grade [WHO/ISUP classification])?

          6. Does the patient have, or has the patient ever had any bladder tumor with histology
             other than transitional cell carcinoma?

          7. Does the patient have, or has the patient ever had, carcinoma in situ (CIS)?

          8. Does the patient have an active urinary tract infection?

          9. Does the patient have a bleeding disorder or a screening platelet count < 100 x 109/L?

         10. Does the patient have any unstable medical condition that would make it unsafe for
             him/her to undergo TURBT under general or spinal anesthesia?

         11. Does the patient have screening hemoglobin < 10 mg/dL, a screening absolute neutrophil
             count < 1.5 x 109/L?

         12. Does the patient have a known immunodeficiency disorder?

         13. Has the patient received any investigational treatment within the past 30 days?

         14. Is the patient breast feeding?

         15. Does the patient have a history of interstitial cystitis?

         16. Does the patient have a history of allergy to red color food dye?

         17. Has the patient had transitional cell carcinoma of the bladder within the past 4
             months?
Clinical trial NCT00216476 (phase 3, status: completed)
Conditions: schizophrenia, psychotic disorders
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F23, F24, F12.159, F12.259, F12.150, F12.151, F12.250
Drugs: aripiprazole, risperidone long acting injectable (lai), quetiapine
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and
             Statistical Manual of Mental Diseases, 4th edition (DSM-IV)

          -  Patients currently treated with oral risperidone, olanzapine or a conventional
             neuroleptic monotherapy at doses not exceeding 6 mg risperdal, 20 mg olanzapine, or a
             conversion dose of 10 mg haloperidol for oral conventional agents

          -  Patients who are stable (judged clinically stable by the investigator and on a stable
             dose of medication for 4 weeks or longer) but not optimally treated (non-satisfactory
             treatment regarding symptoms or adverse events)

        Exclusion Criteria:

          -  Diagnosis other than schizophrenia or schizoaffective disorder by DSM-IV Axis I
             criteria

          -  Patients being treated with antipsychotic agents other than oral risperidone,
             olanzapine or conventional oral neuroleptic agents

          -  Patients with known hypersensitivity to oral risperidone, quetiapine, aripiprazole, or
             who are known non-responders to oral risperidone, quetiapine, aripiprazole or to
             previous treatment with at least 2 antipsychotic agents

          -  Patients treated with mood stabilizers or antidepressants who are not on stable dose
             for at least 3 months before study initiation

          -  Pregnant or nursing females, or those lacking adequate contraception
Clinical trial NCT00345618 (phase 3, status: completed)
Conditions: embolism, thrombosis
ICD codes: I27.82, I76, O88.02, O88.82, T79.0XXS, T79.1XXS, O03.2, I81, K64.5, I51.3, I67.6, I74.11, I74.5, I74.8
Drugs: idrabiotaparinux sodium, warfarin, placebo (for idrabiotaparinux sodium), avidin, placebo (for warfarin), enoxaparin
SMILES: S1SSSSSSS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis

        Exclusion Criteria:

          -  End stage renal failure, hepatic failure, uncontrolled hypertension;

          -  Active bleeding or high risk for bleeding;

          -  Pregnancy or childbearing potential without proper contraceptive measures, threatened
             abortion.

          -  Breastfeeding.

          -  Known allergy to idraparinux or idrabiotaparinux, avidin or egg proteins;

          -  hypersensitivity to warfarin, enoxaparin, heparin or pork product; or any other
             contraindication listed in the labelling of warfarin or enoxaparin;

          -  Indication of prolonged anticoagulation therapy for other reason than PE;

          -  Life expectancy < 6 months;
Clinical trial NCT00391222 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: olanzapine, placebo, risperidone long acting injectable (lai)
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of bipolar I disorder as defined by DSM-IV-TR criteria. All diagnoses will
             be confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I.). Patients
             who present with additional signs or symptoms compatible with Axis I diagnoses of
             social anxiety disorder or generalized anxiety disorder are acceptable. All other
             comorbid or active Axis I diagnoses are excluded. Personality disorders as defined by
             DSM IV TR criteria are acceptable, with the exception of antisocial and borderline
             personality disorders

          -  Must be currently experiencing a manic or mixed episode (acute

          -  YMRS >20 and CGI-S =>4 [moderate]) or must be between mood episodes (non-acute

          -  YMRS <12 and CGI-S=<3 [mild])

          -  Must have had at least 2 bipolar mood (manic, mixed manic, or depressed) episodes,
             exclusive of the current episode (if applicable), during the last year. For non-acute
             subjects (YMRS <12 and CGI-S=<3 [mild]), one manic episode must have occurred within 4
             months of enrollment

          -  Patients who are non-acute (YMRS <12 and CGI-S =<3 [mild]) and are currently receiving
             an antipsychotic other than risperidone or a mood stabilizer must have received this
             other medication at the same dosage for a minimum of 4 weeks and must be either
             experiencing problems of safety or tolerability with the antipsychotic or mood
             stabilizer or request a change of medication

        Exclusion Criteria:

          -  No history of more than 4 mood episodes each year (rapid cycling) during the last 2
             years prior to screening

          -  No history of ADHD, anxiety disorder, or panic disorder as the primary diagnosis

          -  Not meeting DSM-IV-TR criteria for a hypomanic or depressive episode

          -  Not meeting DSM-IV-TR criteria for any comorbid or active Axis I disorder other than
             those specifically allowed in the Inclusion Criteria

          -  Not meeting DSM-IV-TR criteria for antisocial or borderline personality disorder

          -  Not having a chronic or serious general medical illness, including hepatic, renal,
             respiratory, cardiovascular, endocrine, neurologic (including seizure disorder), or
             hematologic disease as determined by the clinical judgment of the investigator
Clinical trial NCT01419197 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab emtansine, treatment of physician's choice
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult participants ≥ 18 years of age.

          -  Histologically or cytologically documented breast cancer.

          -  Metastatic or unresectable locally advanced/recurrent breast cancer.

          -  HER2-positive disease by prospective laboratory confirmation.

          -  Disease progression on the last regimen received as defined by the investigator.

          -  Prior treatment with an trastuzumab, a taxane, and lapatinib.

          -  Disease progression after at least two regimens of HER2-directed therapy in the
             metastatic or unresectable locally advanced/recurrent setting.

          -  Adequate organ function, as evidenced by laboratory results.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          -  Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or multi gated
             acquisition scan.

        Exclusion Criteria:

          -  Chemotherapy ≤ 21 days before first study treatment.

          -  Trastuzumab ≤ 21 days before first study treatment.

          -  Lapatinib ≤ 14 days before first study treatment.

          -  Prior enrollment in a trastuzumab emtansine containing study, regardless whether the
             patient received prior trastuzumab emtansine.

          -  Brain metastases that are untreated or symptomatic, or require any radiation, surgery
             or corticosteroid therapy to control symptoms within 1 month of randomization.
Clinical trial NCT01947855 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, empagliflozin, placebo, placebo, empagliflozin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of type 2 diabetes mellitus prior to informed consent

          -  Male and female patients on diet and exercise regimen for 12 weeks prior to informed
             consent who are:

               -  drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to
                  informed consent or,

               -  pre-treated with one oral antidiabetic drug (except sulfonylurea and
                  thiazolidinedione); the present antidiabetic therapy has to be unchanged for at
                  least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as
                  pre-treatment drug only if the dose is equal or less than a half of daily maximum
                  approval dose.)

          -  Glycosylated haemoglobin (HbA1c) at Visit 1 (screening)

               -  for patients without antidiabetic therapy : HbA1c >=7.0 to =<10.0%

               -  for patients with one oral antidiabetic drug : HbA1c >=7.0 to =<9.5%

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level >240 mg/dL (>13.3 mmol/L)

          -  Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <60
             mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal
             disease (MDRD) formula)

          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks
             prior to informed consent

          -  Indication of liver disease, defined by serum levels of either alanine transaminase
             (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper
             limit of normal (ULN)